多系统缩中的便秘:一项针对中国患者的试点研究.
Yalan Chen1, Hongyan Huang2, Peng Zhang1
1Department of Neurology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
便秘在多系统缩 (MSA) 中很常见,通常出现在运动症状之前. 这是一种非运动性症状.
科学领域:
- 神经学 神经学
- 胃肠病学 胃肠病学
背景情况:
- 多重系统缩 (MSA) 是一种渐进的神经退行性疾病.
- 便秘是MSA中常见的非运动性症状,影响患者的生活质量.
研究的目的:
- 确定MSA的中国患者主观便秘的流行率和临床特征.
- 在MSA中调查便秘发作的时间相对于运动症状的发展.
主要方法:
- 在中国对200名可能的MSA患者进行横截面研究 (2016年2月 - 2021年6月).
- 收集了关于人口统计,便秘 (ROME III标准),运动和非运动症状 (UMSARS) 的数据.
主要成果:
- 便秘患病率在MSA中为53.5%,在MSA-P中为59.7%,在MSA-C中为39.3%.
- MSA-P亚型和更高的UMSARS分数与便秘相关.
- 59.8%的便秘患者在运动发作之前出现症状,之前的间隔较长.
结论:
- 便秘是MSA中非常普遍的早期非运动性症状.
- 了解便秘的时间可能有助于早期的MSA病因研究.
更多相关视频
04:04Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation
Published on: July 5, 2024
03:25Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment
Published on: December 27, 2024
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
Assessment of the Rectum and Anus
Rectal Inspection
Begin by inspecting the perianal and anal areas for color, texture, rashes,...
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Drugs Affecting GI Tract Motility: Other Laxatives
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
